News of the index components SMI

Index

SMI

CH0009980894

Market Closed - Swiss Exchange 19:30:54 01/09/2026 +04			5-day change	1st Jan Change
14,334.79 ^PTS	+0.34%		-1.31%	+8.04%

09-01	Swiss Market Index Recovers; Novartis Gains Amid Positive Late-stage Multiple Sclerosis Drug Data	MT
09-01	SIX Group Logs Higher Turnover from Swiss, Spanish Bourses in August	MT

News of the index components

09-02	Health Care Up on Defensive Bias - Health Care Roundup	DJ
09-01	Nestle Inks $1 Billion Deal to Sell Health-Supplements Brands to Private Equity Firm	DJ
09-01	Nestle to offload mainstream vitamin brands for $1 billion	RE
09-01	Nestle : Nestlé reaches agreement to divest its mainstream vitamins, minerals and supplements business	DJ
09-01	BofA Keeps UBS Group at Buy Amid 'More Lenient' Swiss Capital Requirements Proposal	MT
09-01	Partners Group CEO Rejects Redemption Concerns	MT
09-01	Partners Group: We do not see the case to walk away from H1 earnings.
09-01	UBS Estimates New Capital Demands at $13 Billion Under Swiss Parliament Plan -- Update	DJ
09-01	Scotiabank Appoints Former UBS CEO Ralph Hamers to Its Board	DJ
09-01	UBS says Swiss compromise on bank regulation is still too costly
09-01	Liberty Specialty Markets appoints Mylène Martin-Ahmine Chief Operating Officer for Europe
09-01	Swiss Lawmakers Propose Lower UBS Capital Requirement	MT
09-01	UBS Notes Swiss Upper House's Proposals to Ease Planned New Capital Rules	DJ
09-01	UBS Warns 'Significant' Cost Increases in Swiss Upper Chamber's Recommended Banking Rule Proposals	MT
09-01	Banco BTG Pactual Begins ABB Coverage with Neutral Rating	MT
09-01	UBS says parliamentary proposal would still require an extra $13 billion in capital	RE
09-01	BofA Notes Novartis' Positive Data from Remibrutinib Late-stage Trials	MT
09-01	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
09-01	Roche Enters Licensing Deal for Simcere Zaiming's Antibody for B-cell-mediated Diseases	MT
09-01	Roche signs global licensing pact for Simcere's experimental blood cancer drug	RE
09-01	Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials	DJ
09-01	Roche signs global licensing pact for Simcere's B-cell cancer drug candidate	RE
09-01	Swiss Life's half-year results generate little enthusiasm
09-01	Novartis Reports Positive Late-stage Trial Results for Oral Multiple Sclerosis Treatment	MT
09-01	Partners Group Shares Slide After Drop in Performance Fees, CEO Change	DJ
09-01	Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials	MT
09-01	Swiss finance minister criticises parliamentary step to soften UBS rules	RE
09-01	Swiss Life to Lay Off 600 Employees by 2028	MT
09-01	Partners Group Replaces CEO as Lower Performance Income Weighs on Interim Profit	MT
09-01	Swiss Lawmakers Propose Lower UBS Capital Requirement	MT
09-01	Swiss PMI rises to 57.1 in August	RE
09-01	Novartis Halts Autoimmune Cell Therapy Trials After Patient Deaths	MT
09-01	Novartis MS pill beats older drug in trials, boosts pipeline hopes	RE
09-01	Partners Group Proposes Appointment of Co-CEOs	MT
09-01	Partners CEO to Switch to Investment Role	DJ
09-01	Novartis Drug Meets Key Goal in Late-Stage Multiple Sclerosis Trials	DJ
09-01	Swiss Life to cut up to 600 jobs by end-2028, half of them in Switzerland	RE
09-01	Novartis Suspends Eight Rap-cel Trials After Three Deaths	MT
09-01	Novartis Outlines Positive Data From Phase III Trials of Remibrutinib in RMS	MT
09-01	Partners Group Logs Lower H1 Attributable Profit, Revenue	MT